Cite
HARVARD Citation
Cramer, P. et al. (2018). Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. Leukemia & lymphoma. 59 (9), pp. 2075-2084. [Online].